<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>15622921</identifier>
<setSpec>0556-6177</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Zabalegui, N</dc:author>
<dc:author>Rodríguez Calvillo, M</dc:author>
<dc:author>Panizo, C</dc:author>
<dc:author>Melero, I</dc:author>
<dc:author>Rocha, E</dc:author>
<dc:author>Hernández, M</dc:author>
<dc:author>López Díaz de Cerio, A</dc:author>
<dc:author>Inogés, S</dc:author>
<dc:author>Pérez Calvo, J</dc:author>
<dc:author>Prósper, F</dc:author>
<dc:author>Bendandi, M</dc:author>
<dc:author>Sánchez-Ibarrola, A</dc:author>
<dc:description xml:lang="en">Cancer vaccines are conceived as therapeutic tools, in contrast to the prophylactic vaccines used to fight against infectious diseases. Among the most potent therapeutic vaccines, anti-idiotype vaccination is directed against the tumor idiotype, the only well-characterized tumor antigen displayed in neoplastic B-cells. Anti-idiotype vaccines have demonstrated clinical benefit against follicular lymphoma and are currently being evaluated in two different phase III clinical trials. Additional emerging strategies, which include the use of dendritic cells and the production of vaccines via molecular means will surely allow us to draw important conclusions concerning the treatment of cancer patients.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2004 Jul-Sep </dc:date>
<dc:title xml:lang="es">Pasado, presente y futuro de la vacunación anti-idiotipo.</dc:title>
<dc:title xml:lang="en">[Past, present and future of anti-idiotype vaccination].</dc:title>
<dc:publisher>Revista de medicina de la Universidad de Navarra</dc:publisher>
</metadata>
</record>
</pubmed-document>
